1. Home
  2. Paper
  3. Griffith_2006_J.Natl.Med.Assoc_98_1590

Griffith_2006_J.Natl.Med.Assoc_98_1590

Reference

Title : Safety and efficacy of donepezil in African Americans with mild-to-moderate Alzheimer's disease - Griffith_2006_J.Natl.Med.Assoc_98_1590
Author(s) : Griffith P , Lichtenberg P , Goldman R , Payne-Parrish J
Ref : J Natl Med Assoc , 98 :1590 , 2006
Abstract :

BACKGROUND: African Americans have a higher incidence and prevalence of Alzheimer's disease (AD) than whites but have been underrepresented in clinical trials, including studies of cholinesterase inhibitors. PURPOSE: The purpose of this 12-week, open-label study was to evaluate the efficacy and safety of donepezil in African Americans with mild-to-moderate AD.
METHODS: Efficacy was assessed via the Mini-Mental State Examination (MMSE), Clinician's Interview-Based Impression of Change-Plus interview with the patient and caregiver (CIBIC-Plus) and Fuld Object Memory Evaluation (FOME), a measure that has been validated for use with elderly African Americans.
RESULTS: Significant improvements were observed in cognition (MMSE), global function (CIBIC-Plus) and memory (all four subscales of the FOME). Donepezil was well tolerated; 51% of patients experienced adverse events, most commonly diarrhea (5.6%), hypertension (5.6%) and urinary tract infection (4.8%).
CONCLUSIONS: These results suggest that donepezil is effective and safe in treating African Americans with mild-to-moderate AD, and support the value of FOME in assessing efficacy in AD trials in diverse populations.
PubMedSearch : Griffith_2006_J.Natl.Med.Assoc_98_1590
PubMedID: 17052048

Related information

Citations formats

Griffith P, Lichtenberg P, Goldman R, Payne-Parrish J (2006)
Safety and efficacy of donepezil in African Americans with mild-to-moderate Alzheimer's disease
J Natl Med Assoc 98 :1590

Griffith P, Lichtenberg P, Goldman R, Payne-Parrish J (2006)
J Natl Med Assoc 98 :1590